Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alaplex** is an oral multi-ingredient nutritional supplement marketed by Tetra for management of symptoms associated with peripheral neuropathy, particularly diabetic peripheral neuropathy, including numbness, tingling, burning, and shooting pain in the feet and legs. The current formulation is supplied as a veggie capsule and combines alpha-lipoic acid, benfotiamine, neurotropic B vitamins including L-methylfolate calcium, and additional nutritional ingredients intended to support peripheral nerve function, cellular energy metabolism, and antioxidant defenses. It is a dietary supplement rather than an FDA-approved pharmaceutical drug. ([thetetracorp.com](https://www.thetetracorp.com/alaplex/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alaplex.